These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 26883681)

  • 1. Increased soluble CD72 in systemic lupus erythematosus is in association with disease activity and lupus nephritis.
    Vadasz Z; Goldeberg Y; Halasz K; Rosner I; Valesini G; Conti F; Perricone C; Sthoeger Z; Bezalel SR; Tzioufas AG; Levin NA; Shoenfeld Y; Toubi E
    Clin Immunol; 2016 Mar; 164():114-8. PubMed ID: 26883681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A regulatory role for CD72 expression on B cells in systemic lupus erythematosus.
    Vadasz Z; Haj T; Balbir A; Peri R; Rosner I; Slobodin G; Kessel A; Toubi E
    Semin Arthritis Rheum; 2014 Jun; 43(6):767-71. PubMed ID: 24461079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD40 and CD72 expression and prognostic values among children with systemic lupus erythematosus: a case-control study.
    Asmiyou A; Bakr AM; Shahin DA; Wahba Y
    Lupus; 2020 Sep; 29(10):1270-1276. PubMed ID: 32700598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Down-regulation of CD72 and increased surface IgG on B cells in patients with lupus nephritis.
    Nakano S; Morimoto S; Suzuki J; Mitsuo A; Nakiri Y; Katagiri A; Nozawa K; Amano H; Tokano Y; Hashimoto H; Takasaki Y
    Autoimmunity; 2007 Feb; 40(1):9-15. PubMed ID: 17364492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time.
    Becker-Merok A; Nikolaisen C; Nossent HC
    Lupus; 2006; 15(9):570-6. PubMed ID: 17080911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased mutations of CD72 transcript in B-lymphocytes from adolescent patients with systemic lupus erythematosus.
    Kaneko U; Toyabe S; Hara M; Uchiyama M
    Pediatr Allergy Immunol; 2006 Dec; 17(8):565-71. PubMed ID: 17121583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum free light chains as biomarkers for systemic lupus erythematosus disease activity.
    Aggarwal R; Sequeira W; Kokebie R; Mikolaitis RA; Fogg L; Finnegan A; Plaas A; Block JA; Jolly M
    Arthritis Care Res (Hoboken); 2011 Jun; 63(6):891-8. PubMed ID: 21312346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha-actinin-binding antibodies in relation to systemic lupus erythematosus and lupus nephritis.
    Becker-Merok A; Kalaaji M; Haugbro K; Nikolaisen C; Nilsen K; Rekvig OP; Nossent JC
    Arthritis Res Ther; 2006; 8(6):R162. PubMed ID: 17062137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD69 to CD3 ratio of peripheral blood mononuclear cells as a marker to monitor systemic lupus erythematosus disease activity.
    Su CC; Shau WY; Wang CR; Chuang CY; Chen CY
    Lupus; 1997; 6(5):449-54. PubMed ID: 9229364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated production of serum B-cell-attracting chemokine-1 (BCA-1/CXCL13) is correlated with childhood-onset lupus disease activity, severity, and renal involvement.
    Ezzat M; El-Gammasy T; Shaheen K; Shokr E
    Lupus; 2011 Jul; 20(8):845-54. PubMed ID: 21576203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-chromatin and anti-C1q antibodies in systemic lupus erythematosus compared to other systemic autoimmune diseases.
    Braun A; Sis J; Max R; Mueller K; Fiehn C; Zeier M; Andrassy K
    Scand J Rheumatol; 2007; 36(4):291-8. PubMed ID: 17763207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum ferritin level correlates with SLEDAI scores and renal involvement in SLE.
    Tripathy R; Panda AK; Das BK
    Lupus; 2015 Jan; 24(1):82-9. PubMed ID: 25253568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD72 polymorphisms associated with alternative splicing modify susceptibility to human systemic lupus erythematosus through epistatic interaction with FCGR2B.
    Hitomi Y; Tsuchiya N; Kawasaki A; Ohashi J; Suzuki T; Kyogoku C; Fukazawa T; Bejrachandra S; Siriboonrit U; Chandanayingyong D; Suthipinittharm P; Tsao BP; Hashimoto H; Honda Z; Tokunaga K
    Hum Mol Genet; 2004 Dec; 13(23):2907-17. PubMed ID: 15459183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The expressions of Toll-like receptor 9 and T-bet in circulating B and T cells in newly diagnosed, untreated systemic lupus erythematosus and correlations with disease activity and laboratory data in a Chinese population.
    Wu O; Chen GP; Chen H; Li XP; Xu JH; Zhao SS; Sheng J; Feng JB; Cai J; Fang XH; Zhang WH; Li LH; Zhang N; Li J; Li JJ; Pan FM; Wang CZ; Ye DQ
    Immunobiology; 2009; 214(5):392-402. PubMed ID: 19362685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-nucleosome antibodies in patients with systemic lupus erythematosus: potential utility as a diagnostic tool and disease activity marker and its comparison with anti-dsDNA antibody.
    Saigal R; Goyal LK; Agrawal A; Mehta A; Mittal P; Yadav RN; Meena PD; Wadhvani D
    J Assoc Physicians India; 2013 Jun; 61(6):372-7. PubMed ID: 24640201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human CD72 splicing isoform responsible for resistance to systemic lupus erythematosus regulates serum immunoglobulin level and is localized in endoplasmic reticulum.
    Hitomi Y; Adachi T; Tsuchiya N; Honda Z; Tokunaga K; Tsubata T
    BMC Immunol; 2012 Dec; 13():72. PubMed ID: 23268649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral circulating activated b-cell populations are associated with nephritis and disease activity in patients with systemic lupus erythematosus.
    Dolff S; Wilde B; Patschan S; Dürig J; Specker C; Philipp T; Kribben A; Witzke O
    Scand J Immunol; 2007 Nov; 66(5):584-90. PubMed ID: 17868260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-nucleosome and anti-chromatin antibodies are present in active systemic lupus erythematosus but not in the cutaneous form of the disease.
    Souza A; da Silva LM; Oliveira FR; Roselino AM; Louzada-Junior P
    Lupus; 2009 Mar; 18(3):223-9. PubMed ID: 19213860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral blood CD5+ B cell subset in the remission phase of systemic connective tissue diseases.
    Markeljević J; Batinić D; Uzarević B; Bozikov J; Cikes N; Babić-Naglić D; Horvat Z; Marusić M
    J Rheumatol; 1994 Dec; 21(12):2225-30. PubMed ID: 7535356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-nucleosome antibodies as a disease marker in systemic lupus erythematosus and its correlation with disease activity and other autoantibodies.
    Pradhan VD; Patwardhan MM; Ghosh K
    Indian J Dermatol Venereol Leprol; 2010; 76(2):145-9. PubMed ID: 20228543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.